Overview

Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

Status:
Terminated

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.

Phase:

Phase 3

Details

Lead Sponsor:

BioVex Limited

Collaborator:

Amgen

Treatments:

Cisplatin
Talimogene laherparepvec